191 related articles for article (PubMed ID: 38237984)
21. Mechanistic understanding of innate and adaptive immune responses in SARS-CoV-2 infection.
Balkhi MY
Mol Immunol; 2021 Jul; 135():268-275. PubMed ID: 33940513
[TBL] [Abstract][Full Text] [Related]
22. Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines.
Lee S; Channappanavar R; Kanneganti TD
Trends Immunol; 2020 Dec; 41(12):1083-1099. PubMed ID: 33153908
[TBL] [Abstract][Full Text] [Related]
23. Structural insights into the distinctive RNA recognition and therapeutic potentials of RIG-I-like receptors.
Batool M; Kim MS; Choi S
Med Res Rev; 2022 Jan; 42(1):399-425. PubMed ID: 34287999
[TBL] [Abstract][Full Text] [Related]
24. TLRs: Innate Immune Sentries against SARS-CoV-2 Infection.
Mantovani S; Oliviero B; Varchetta S; Renieri A; Mondelli MU
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175768
[TBL] [Abstract][Full Text] [Related]
25. Innate immunity, cytokine storm, and inflammatory cell death in COVID-19.
Karki R; Kanneganti TD
J Transl Med; 2022 Nov; 20(1):542. PubMed ID: 36419185
[TBL] [Abstract][Full Text] [Related]
26. An Update on Innate Immune Responses during SARS-CoV-2 Infection.
Zhang Y; Chen S; Jin Y; Ji W; Zhang W; Duan G
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696490
[TBL] [Abstract][Full Text] [Related]
27. Innate immunity: the first line of defense against SARS-CoV-2.
Diamond MS; Kanneganti TD
Nat Immunol; 2022 Feb; 23(2):165-176. PubMed ID: 35105981
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection.
Farooq M; Khan AW; Ahmad B; Kim MS; Choi S
Front Pharmacol; 2022; 13():915565. PubMed ID: 35847031
[TBL] [Abstract][Full Text] [Related]
29. Innate Immune Response in SARS-CoV-2 Infection.
Schiuma G; Beltrami S; Bortolotti D; Rizzo S; Rizzo R
Microorganisms; 2022 Feb; 10(3):. PubMed ID: 35336077
[TBL] [Abstract][Full Text] [Related]
30. Cellular Sensors and Viral Countermeasures: A Molecular Arms Race between Host and SARS-CoV-2.
Sun H; Chan JF; Yuan S
Viruses; 2023 Jan; 15(2):. PubMed ID: 36851564
[TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways.
Han L; Zhuang MW; Deng J; Zheng Y; Zhang J; Nan ML; Zhang XJ; Gao C; Wang PH
J Med Virol; 2021 Sep; 93(9):5376-5389. PubMed ID: 33913550
[TBL] [Abstract][Full Text] [Related]
32. The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity.
Gu W; Gan H; Ma Y; Xu L; Cheng ZJ; Li B; Zhang X; Jiang W; Sun J; Sun B; Hao C
Virol J; 2022 Mar; 19(1):49. PubMed ID: 35305698
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics.
Beacon TH; Su RC; Lakowski TM; Delcuve GP; Davie JR
IUBMB Life; 2020 Nov; 72(11):2331-2354. PubMed ID: 32936531
[TBL] [Abstract][Full Text] [Related]
34. Interferon alpha inducible protein 6 is a negative regulator of innate immune responses by modulating RIG-I activation.
Villamayor L; Rivero V; López-García D; Topham DJ; Martínez-Sobrido L; Nogales A; DeDiego ML
Front Immunol; 2023; 14():1105309. PubMed ID: 36793726
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response.
Liu Y; Qin C; Rao Y; Ngo C; Feng JJ; Zhao J; Zhang S; Wang TY; Carriere J; Savas AC; Zarinfar M; Rice S; Yang H; Yuan W; Camarero JA; Yu J; Chen XS; Zhang C; Feng P
mBio; 2021 Oct; 12(5):e0233521. PubMed ID: 34544279
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity.
Gori Savellini G; Anichini G; Gandolfo C; Cusi MG
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452305
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory cell death, PANoptosis, screen identifies host factors in coronavirus innate immune response as therapeutic targets.
Malireddi RKS; Bynigeri RR; Mall R; Connelly JP; Pruett-Miller SM; Kanneganti TD
Commun Biol; 2023 Oct; 6(1):1071. PubMed ID: 37864059
[TBL] [Abstract][Full Text] [Related]
38. The intersection molecule MDA5 in Cancer and COVID-19.
Jin R; Cao X; Lu M; Gao Q; Ma T
Front Immunol; 2022; 13():963051. PubMed ID: 36119095
[TBL] [Abstract][Full Text] [Related]
39. Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation.
Beirag N; Kumar C; Madan T; Shamji MH; Bulla R; Mitchell D; Murugaiah V; Neto MM; Temperton N; Idicula-Thomas S; Varghese PM; Kishore U
Front Immunol; 2022; 13():960733. PubMed ID: 35967323
[TBL] [Abstract][Full Text] [Related]
40. Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators.
Ricci D; Etna MP; Rizzo F; Sandini S; Severa M; Coccia EM
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
